Ann: GENERAL: FPH: CAREFUSION & FPH RENEW EXCLUSI

• Release Date: 09/02/12 10:36
• Summary: GENERAL: FPH: CAREFUSION & FPH RENEW EXCLUSIVE DISTRIBUTION AGREEMENT
• Price Sensitive: No
• Download Document  5.21KB

					

FPH
09/02/2012 08:36
GENERAL

REL: 0836 HRS Fisher & Paykel Healthcare Corporation Limited

GENERAL: FPH: CAREFUSION & FPH RENEW EXCLUSIVE DISTRIBUTION AGREEMENT

CAREFUSION & FISHER & PAYKEL HEALTHCARE RENEW EXCLUSIVE DISTRIBUTION
AGREEMENT FOR U.S. HOSPITAL MARKET

Contacts:

Media:  Kristen Cardillo (CareFusion)
 (858) 617-2317
 [email protected]
Marcus Driller
(Fisher & Paykel Healthcare)
 +64 9 574 0110
 [email protected]

Investors:   Jim Mazzola (CareFusion)
 (858) 617-1203
 [email protected]

Marcus Driller
(Fisher & Paykel Healthcare)
 +64 9 574 0110
 [email protected]

CAREFUSION AND FISHER & PAYKEL HEALTHCARE RENEW EXCLUSIVE DISTRIBUTION
AGREEMENT FOR U.S. HOSPITAL MARKET

SAN DIEGO, Feb. 8, 2012 - CareFusion, a leading, global medical technology
company, and Fisher & Paykel Healthcare, a leading designer, manufacturer and
marketer of products and systems for use in respiratory care, acute care and
the treatment of obstructive sleep apnea, today announced a three-year
renewal of their longstanding agreement providing CareFusion the exclusive
right to distribute Fisher & Paykel Healthcare products into the U.S.
hospital market.
"For more than 25 years, we have partnered with Fisher & Paykel Healthcare to
bring its portfolio of clinically differentiated respiratory solutions to
U.S. hospitals," said Vivek Jain, president of the Procedural Solutions
segment for CareFusion. "As we extend and strengthen our strategic
relationships with proven partners like Fisher & Paykel Healthcare, our
customers benefit from continued access to market-leading technologies that
help improve the cost, quality and safety of patient care."
Under the agreement, CareFusion, through its AirLife(TM) Respiratory
Consumables business, will continue to serve as the exclusive U.S.
distributor of Fisher & Paykel Healthcare's extensive portfolio of
respiratory consumable products, including the MR850 Heated Humidification
System with Evaqua(TM) circuit technology, AIRVO(TM) high flow device,
Optiflow(TM) nasal cannula, and FlexiFit(TM) non-invasive interfaces.
"Through our extended partnership, Fisher & Paykel Healthcare can leverage
CareFusion's experience and expertise in the respiratory and acute care
markets to continue to grow our business in the United States," said Justin
Callahan, president of U.S. operations for Fisher & Paykel Healthcare. "We
have been pleased with the strong relationships CareFusion's AirLife team has
established with U.S. hospitals and look forward to continuing our
longstanding partnership with CareFusion."

About CareFusion Corporation
CareFusion (NYSE: CFN) is a global corporation serving the health care
industry with products and services that help hospitals measurably improve
the safety and quality of care. The company develops market-leading
technologies including Alaris infusion pumps, Pyxis automated dispensing and
patient identification systems, AVEA, AirLife and LTV series ventilation and
respiratory products, ChloraPrep products, MedMined services for data mining
surveillance, Nicolet neurological monitoring and diagnostic products, V.
Muellersurgical instruments, and an extensive line of products that support
interventional medicine. CareFusion employs more than 14,000 people across
its global operations. More information may be found at www.carefusion.com.

About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare (NZSX: FPH, ASX: FPH) is a leading designer,
manufacturer and marketer of products and systems for use in respiratory
care, acute care and the treatment of obstructive sleep apnea. The company's
products are sold in more than 120 countries worldwide.  For more information
about the company, visit www.fphcare.com.
###

Cautions Concerning Forward-looking Statements

This news release and the information contained herein contains
forward-looking statements addressing expectations, prospects, estimates and
other matters that are dependent upon future events or developments. The
matters discussed in these forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ materially from
those projected, anticipated or implied. Forward-looking statements include,
but are not limited to, statements about the expected benefits of the
distribution agreement between CareFusion and Fisher & Paykel Healthcare, as
well as future growth opportunities that may result from this and other
relationships between the companies. The forward-looking statements contained
herein are based on current expectations and assumptions and not on
historical facts, and actual results may differ materially if CareFusion and
Fisher & Paykel Healthcare fail to achieve the intended benefits of the
agreement.  Additional factors that may affect CareFusion's future results
are described in its Form 10-K, Form 10-Q and Form 8-K reports (including all
amendments to those reports) and exhibits to those reports that CareFusion
files with the U.S. Securities and Exchange Commission. Except to the limited
extent required by applicable law, CareFusion undertakes no obligation to
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
End CA:00219332 For:FPH    Type:GENERAL    Time:2012-02-09 08:36:08